MedTrace Logo

Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

NCT04516811 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-05-08

No results posted yet for this study

Summary

A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19

Conditions

Interventions

BIOLOGICAL

COVID-19 convalescent plasma (CCP) plus standard of care (SOC)

A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.

BIOLOGICAL

Standard of care (SOC) plus placebo

A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines

Sponsors & Collaborators

  • South African National Blood Service

    lead OTHER

Principal Investigators

  • Sean Wasserman, A/Professor · CIDRI-Africa, University of Cape Town

  • Karin vandenBerg, Dr · South African National Blood Service

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-12-30
Completion
2022-07-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516811 on ClinicalTrials.gov